UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 70

Sortiert nach

Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo

Blood, 2007-02, Vol.109 (4), p.1503-1506

2007

Volltextzugriff (PDF)

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

Blood, 2008-04, Vol.111 (8), p.3931-3940

2008

Volltextzugriff (PDF)

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf−/− mouse model

Proceedings of the National Academy of Sciences - PNAS, 2017-03, Vol.114 (12), p.3151-3156

2017

Volltextzugriff (PDF)

Talin is required for integrin-mediated platelet function in hemostasis and thrombosis

The Journal of experimental medicine, 2007-12, Vol.204 (13), p.3103-3111

2007

Volltextzugriff (PDF)

Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach

ACS medicinal chemistry letters, 2016-08, Vol.7 (8), p.735-740

2016

Volltextzugriff (PDF)

Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion

Blood, 2007-11, Vol.110 (9), p.3183-3191

2007

Volltextzugriff (PDF)

Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket

ACS medicinal chemistry letters, 2016-08, Vol.7 (8), p.730-734

2016

Volltextzugriff (PDF)

Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach

ACS medicinal chemistry letters, 2017-03, Vol.8 (3), p.338-343

2017

Volltextzugriff (PDF)

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

Therapeutic advances in medical oncology, 2019, Vol.11, p.1758835919889001

2019

Volltextzugriff (PDF)

DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway

Oncotarget, 2020-03, Vol.11 (11), p.956-968

2020

Volltextzugriff (PDF)

Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition

Science advances, 2020-06, Vol.6 (25), p.eabb2210-eabb2210

2020

Volltextzugriff (PDF)

A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression

PloS one, 2019, Vol.14 (10), p.e0221635-e0221635

2019

Volltextzugriff (PDF)

A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family

Haematologica (Roma), 2008-05, Vol.93 (5), p.706-714

2008

Volltextzugriff (PDF)

Zim17, a Novel Zinc Finger Protein Essential for Protein Import into Mitochondria

The Journal of biological chemistry, 2004-11, Vol.279 (48), p.50243-50249

2004

Volltextzugriff (PDF)

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening

Cell, 2017-07, Vol.170 (3), p.577-592.e10

2017

Volltextzugriff (PDF)

Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation

Clinical cancer research, 2019-05, Vol.25 (10), p.3164-3175

2019

Volltextzugriff (PDF)

A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders

The New England journal of medicine, 2005-04, Vol.352 (17), p.1779-1790

2005

Volltextzugriff (PDF)

Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts

Blood, 2020-10, Vol.136 (17), p.1983-1988

2020

Volltextzugriff (PDF)

Abstract P5-13-18: Upregulation of immune response biomarkers by ribociclib plus endocrine therapy (ET) in paired tumor samples from phase I studies

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-13-18

2022

Volltextzugriff (PDF)

Targeting multiple nodes of MLL complexes to improve leukemia therapy

Oncotarget, 2017-10, Vol.8 (53), p.90614-90615

2017

Volltextzugriff (PDF)

Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR + Advanced Breast Cancer

Clinical cancer research, 2021-01, Vol.27 (2), p.418-428

2021

Volltextzugriff (PDF)

Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2024-06, Vol.192, p.107820, Article 107820

2024

Volltextzugriff (PDF)

The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

Oncotarget, 2018-10, Vol.9 (81), p.35226-35240

2018

Volltextzugriff (PDF)

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma

Journal of neuro-oncology, 2020-01, Vol.146 (1), p.79-89

2020

Volltextzugriff (PDF)

1 – 25 von 70

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(64)

Publikationsform

Artikel
(69)
Buchkapitel
(1)

Sprache

Englisch
(70)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

Science & Technology
(38)
Life Sciences & Biomedicine
(35)
Humans
(20)
Animals
(13)
Mice
(12)
Female
(11)
Male
(11)
Oncology
(11)
Biological And Medical Sciences
(9)
Hematology
(8)
Medical Sciences
(8)
Adult
(7)
Middle Aged
(7)
Aged
(6)
Cell Biology
(6)
Dot1l
(6)
Hematologic And Hematopoietic Diseases
(6)
Medicin Och Hälsovetenskap
(6)
Cell Line, Tumor
(5)
Genetics
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(15)
Cancer Research
(10)
Acs Medicinal Chemistry Letters
(4)
Oncotarget
(4)
Nature Genetics
(3)
Proceedings Of The National Academy Of Sciences - Pnas
(3)
Cancer Discovery
(2)
Clinical Cancer Research
(2)
Lancet Neurology
(2)
Neurology
(2)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf−/− mouse model

Talin is required for integrin-mediated platelet function in hemostasis and thrombosis

Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach

Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion

Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket

Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway

Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition

A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression

A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family

Zim17, a Novel Zinc Finger Protein Essential for Protein Import into Mitochondria

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening

Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation

A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma

Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts

Abstract P5-13-18: Upregulation of immune response biomarkers by ribociclib plus endocrine therapy (ET) in paired tumor samples from phase I studies

Targeting multiple nodes of MLL complexes to improve leukemia therapy

Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR + Advanced Breast Cancer

Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer

The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma

Suchergebnisse filtern